4SC (VSC)

Business description

4SC is a Munich-based cancer R&D company. Epigenetic compound resminostat (HDAC inhibitor) is the lead candidate for CTCL (Phase II initiated Q416), partnered with Yakult Honsha and Menarini. 4SC is partnered with Link Health for a Phase I oncology asset.

Stock data

Market cap.€50m
Last close€2.64
High / Low (52 weeks)€4.1 / €2.1
Stock market listingDE
Forecast net cash (€m)8.4
Forecast gearing ratio (%)N/A
TeamHealthcare
SectorPharmaceutical & healthcare

Price performance

%1m3m12m
Actual(8.6)9.4(27.6)
Relative *(10.2)(0.9)(43.8)

* % Relative to local index

Other companies in sector Show

aap Implantate Aastrom Biosciences
AB Science Abcam
Abivax SA Ablynx
Abzena Acarix
Achillion Pharmaceuticals Acorda Therapeutics
Actinium Pharmaceuticals Active Biotech
Acucela Addex Therapeutics
Adherium Advanced Medical Solutions
Aegerion Pharmaceuticals Aeterna Zentaris
AFT Pharmaceuticals Agennix
Akari Therapeutics Alchemia
Alexza Pharmaceuticals Algeta
Alimera Sciences ALK Abello
Alkermes Allergy Therapeutics
Alliance Pharma Allium Medical Solutions
Alnylam Pharmaceuticals Amarantus BioScience
Amarin Amplifon
AmpliPhi Biosciences Angle
Animalcare Group Anteo Diagnostics
Anthera Pharmaceuticals Aratana Therapeutics
Ardea Biosciences Ardelyx
Arena Pharmaceuticals arGEN-X
Argos Therapeutics Ariad Pharmaceuticals
Ark Therapeutics Group ArQule
Array BioPharma Arrowhead Research Corporation
Ascendis Pharma Astex Pharmaceuticals
Athersys Atossa Genetics
Avacta Group Avalanche Biotechnologies
AVEO Pharmaceuticals Avita Medical
Balda Basilea Pharmaceutica
Bavarian Nordic BB Healthcare Trust
Bellus Health Benitec Biopharma
BioCryst Pharmaceuticals BioInvent
BioLight Life Sciences BioLineRx
Biondvax Pharmaceuticals Bionomics
Bionor Pharma Biota Holdings
Biotie Therapies Corp Biotron
Bluebird Bio Bone Therapeutics
BrainStorm Cell Therapeutics BTG
C4X Discovery Holdings Can-Fite BioPharma
Capstone Therapeutics Carmat
Cell Therapy Celldex Therapeutics
Cellectis Celyad
Cerulean Pharma Circadian Technologies
Clavis Pharma Cleveland BioLabs
Clinigen Group Clinuvel
co.don AG Collplant Holdings
Consort Medical Corium International
Crescendo Crossject
Curis Cytori Therapeutics
Cytos Biotechnology CytRx Corporation
DBV Technologies Dechra Pharmaceuticals
Delcath Systems Deltex Medical
Derma Sciences DiaSorin
Diaxonhit e-Therapeutics
Egalet Corporation EKF Diagnostics
Emergent BioSolutions Endocyte
Epigenomics Erytech Pharma
Esperion Therapeutics Evotec
Exact Sciences Exelixis
Factor Therapeutics Formycon
Forward Pharma Fresenius SE & Co. KGaA
Futura Medical Galapagos
Galmed Pharmaceuticals Genedrive
Genfit Genmab
Genticel GeoVax
GI Dynamics Gilead Sciences
GNI Group Ltd GW Pharmaceuticals
Halozyme Therapeutics Horizon Discovery
Hutchison China MediTech Hybrigenics
iCo Therapeutics Idenix
Immune Pharmaceuticals Immunicum
Immunodiagnostic Systems Holdings Immunovia
ImmuPharma Imprimis Pharmaceuticals
Imugene Incyte Corporation
Infinity Pharmaceuticals Innate Pharma
Insmed Intec Pharma
International Stem Cell Corporation Invion
Ion Beam Applications Ipsogen
Iridex Ironwood Pharmaceuticals
Islet Sciences Ixico
KaloBios Pharmaceuticals Karolinska Development
Keryx Biopharmaceuticals Kiadis Pharma
LCA-Vision LeMaitre Vascular
Lifeline Scientific LifeWatch
Ligand Pharmaceuticals Lipocine
Lombard Medical Technologies MagForce
Mast Therapeutics Medcom Tech
Medicago MediciNova
Medigene Medivir
Merrimack Pharmaceuticals Merrion Pharmaceuticals
Mesoblast MethylGene
Midatech Pharma MISSION Therapeutics
Molecular Partners MolMed
Mologen AG Momenta Pharmaceuticals
MorphoSys Nanobiotix
Nanosonics Nektar Therapeutics
NeoStem Neovacs
NetScientific Newron Pharmaceuticals
Nexstim NicOx
NMC Health NorDiag
Nordion NovaBay Pharmaceuticals
Novacyt Novogen
NPS Pharmaceuticals Nuevolution
Ocata Therapeutics Omega Diagnostics Group
Omeros Corporation OncoGenex Pharmaceuticals
Oncolytics Biotech Inc OncoMed Pharmaceuticals
Onconova Therapeutics Oncothyreon
Onxeo Onyx Pharmaceuticals
Opexa Therapeutics OPMEDIC Group
Optos Orexigen Therapeutics
Orexo Oryzon Genomics
Ossur OvaScience
Oxford BioMedica Pacific Edge
Paion Paladin Labs
Patheon PDL BioPharma
Pharmacyclics PharmaMar
Pharmaxis Pharming Group
Photocure Phylogica
Pixium Vision Pluristem Therapeutics
Prescient Therapeutics Prima BioMed
Probiodrug ProMetic Life Sciences
Prosensa Proteome Sciences
PsiOxus QRxPharma
Quantum Genomics Quantum Pharmaceuticals
RedHill Biopharma Regeneus
Relmada Therapeutics ReNeuron Group
Resverlogix REVA Medical
RXi Pharmaceuticals Sangamo BioSciences
Sarepta Therapeutics Sartorius
Scancell Selvita
Shire Silence Therapeutics
Simavita Sinclair Pharma
Sirtex Medical Skyepharma
Smith & Nephew Sobi
Sosei Group Corporation Source Bioscience
SQI Diagnostics Stallergenes
StemCells Stentys
Stratec Biomedical Sucampo Pharmaceuticals
Sunesis Pharmaceuticals Surgical Innovations
Sygnis SymBio Pharmaceuticals
Synairgen Synergy Health
Synta Pharmaceuticals TearLab Corp
Tekmira TESARO
Theraclion Threshold Pharmaceuticals
ThromboGenics TiGenix
Tissue Regenix Tissue Therapies
Titan Pharmaceuticals Tonix Pharmaceuticals
Topotarget Touchstone Innovations
Touchstone Innovations Transgene
Trillium Therapeutics Trimel Pharmaceuticals
TruScreen Ltd TxCell
UCB UDG Healthcare
uniQure NV Universal Biosensors
VBI Vaccines Vectura
Verastem Verisante Technology
Vernalis Verona Pharma
Vertex Pharmaceuticals Viralytics
ViroPharma Vivalis
Vivus VolitionRx
WaferGen Biosystems Wilex
Xbrane Xencor
Zafgen Zealand Pharma
Ziopharm Oncology

Company news

Evonik to Buy Performance Materials from Air Products (APD) in $3.8B Deal

Fri, 06 May 2016 11:37:30 GMT

Karnataka-Kerala inter-state road gets environment ministry nod

Sat, 11 May 2013 18:48:10 GMT

Notable Mergers and Acquisitions 7/16: (MGA) (EBAY) (EPD)/(GEL) (AXE)/(HDS)

Thu, 16 Jul 2015 13:54:24 GMT

Y/E Dec Revenue (€m) EBITDA (€m) PBT (€m) EPS (c) P/E (x) P/CF (x)
2014A 7.1 (8.3) (8.8) (87.6) N/A N/A
2015A 3.3 (7.9) (8.4) (58.6) N/A N/A
2016E 3.8 (12.8) (12.9) (67.9) N/A N/A
2017E 4.0 (5.9) (6.0) (31.1) N/A N/A

Last updated on 19/12/2016

Investment summary

4SC has announced the enrolment of the first patient in its RESMAIN study. This is a pivotal study to evaluate resminostat (RES), an epigenetic cancer drug for maintenance treatment (MAIN) in patients with advanced-stage cutaneous T-cell lymphoma (CTCL). We expect early data to be reported in 2019. We increase our rNPV to €120m from €117m as we have raised the probability of the CTCL programme in Europe to 30% (from 20%) following the initiation of the trial.

Last updated on 19/12/2016

Industry outlook

Resminostat could become the first HDAC inhibitor to gain EU approval for CTCL (vs four HDACs approved in the US). CTCL has been validated as a target indication for HDACs, with vorinostat (Merck & Co) and romidepsin (Celgene) FDA-approved on Phase II data.

Last updated on 29/11/2016

Key management

Jason Loveridge, CEO
Dr. Anna Niedl , Manager Corporate Communications and Investor
Wolfgang Güssgen, Head of Corporate Communications and IR

Company address

Am Klopferspitz 19a
82152
Planegg-Martinsried
Germany
+49 (0)89 700763-0
View website